NCT01827358View on ClinicalTrials.gov

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 7, 2016

Study Completion Date

June 21, 2016

Conditions
Staphylococcal Infection
Interventions
DRUG

Mupirocin calcium

Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications

DRUG

Mupirocin calcium

Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications

Trial Locations (6)

30308-2208

Emory University Hospital Midtown - Neonatal Intensive Care Unit, Atlanta

21201-1595

University of Maryland Medical Center - Children's Hospital - Neonatal Intensive Care Unit, Baltimore

64108-4619

Children's Mercy Hospital and Clinics - Infectious Diseases, Kansas City

63104-1003

Saint Louis University School of Medicine - Cardinal Glennon Children's Medical Center - NICU, St Louis

45229-3039

Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati

37232-2573

Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01827358 - Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants | Biotech Hunter | Biotech Hunter